Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

References

• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Chow PK, Choo SP, Ng DC, et al. Heterogeneity and subclassification of Barcelona clinic liver cancer stage B. Liver Cancer. 2016;5(2):91–96. doi:10.1159/000367768
   PubMed Web of Science ®Google Scholar
• Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99(12):1622–1629. doi:10.1002/bjs.8915
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519–524. doi:10.1053/jhep.2002.32089
   PubMed Web of Science ®Google Scholar
• Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62(2):440–451. doi:10.1002/hep.27745
   PubMed Web of Science ®Google Scholar
• Kim H, Ahn SW, Hong SK, et al. Survival benefit of liver resection for Barcelona clinic liver cancer stage B hepatocellular carcinoma. Br J Surg. 2017;104(8):1045–1052. doi:10.1002/bjs.10541
   PubMed Web of Science ®Google Scholar
• Research, European Organisation For, Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–535. doi:10.1038/nrclinonc.2014.122
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-5
   PubMed Web of Science ®Google Scholar
• Giannini EG, Moscatelli A, Pellegatta G, et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol. 2016;111(1):70–77. doi:10.1038/ajg.2015.389
   PubMed Web of Science ®Google Scholar
• Scaffaro LA, Stella SF, Alvares-Da-Silva MR, Kruel CD. Survival rates according to Barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol. 2015;7(3):628–632. doi:10.4254/wjh.v7.i3.628
   PubMedGoogle Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Ho MC, Hasegawa K, Chen XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2016;5(4):245–256. doi:10.1159/000449336
   PubMed Web of Science ®Google Scholar
• Chang YJ, Chung KP, Chang YJ, Chen LJ. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg. 2016;103(11):1513–1520. doi:10.1002/bjs.10196
   PubMed Web of Science ®Google Scholar
• Koh YX, Tan HL, Lye WK, et al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona clinic liver cancer stage hepatocellular carcinoma: a critical appraisal of the evidence. World J Hepatol. 2018;10(6):433–447. doi:10.4254/wjh.v10.i6.433
   PubMed Web of Science ®Google Scholar
• Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257(5):929–937. doi:10.1097/SLA.0b013e31828329b8
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12(1):10. doi:10.1038/nrclinonc.2014.122-c1
   PubMed Web of Science ®Google Scholar
• Jung YK, Jung CH, Seo YS, et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol. 2016;31(2):467–474. doi:10.1111/jgh.13152
   PubMed Web of Science ®Google Scholar
• Wan L, Dong DH, Wu XN, et al. Single large nodule (>5 cm) prognosis in hepatocellular carcinoma: kinship with Barcelona Clinic Liver Cancer (BCLC) stage A or B? Med Sci Monit. 2020;26:e926797. doi:10.12659/MSM.926797
   PubMed Web of Science ®Google Scholar
• Cho Y, Sinn DH, Yu SJ, et al. Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B. PLoS One. 2016;11(11):e0165722. doi:10.1371/journal.pone.0165722
   PubMed Web of Science ®Google Scholar
• Chua DW, Koh YX, Allen JC, et al. Impact of spontaneous rupture on the survival outcomes after liver resection for hepatocellular carcinoma: a propensity matched analysis comparing ruptured versus non-ruptured tumors. Eur J Surg Oncol. 2019;45(9):1652–1659. doi:10.1016/j.ejso.2019.03.044
   PubMed Web of Science ®Google Scholar
• Goh BKP, Syn N, Koh YX, et al. Comparison between short and long-term outcomes after minimally invasive versus open primary liver resections for hepatocellular carcinoma: a 1:1 matched analysis. J Surg Oncol. 2021;124(4):560–571. doi:10.1002/jso.26556
   PubMed Web of Science ®Google Scholar
• Koh YX, Tan HJ, Liew YX, et al. Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg. 2019;229(5):467–78.e1. doi:10.1016/j.jacc.2019.08.565
   PubMed Web of Science ®Google Scholar
• Linn YL, Chee MY, Koh YX, et al. Actual 10-year survivors and 10-year recurrence free survivors after primary liver resection for hepatocellular carcinoma in the 21st century: a single institution contemporary experience. J Surg Oncol. 2021;123(1):214–221. doi:10.1002/jso.26259
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–359. doi:10.1055/s-0032-1329906
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, for the CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 7(3): e1000251
   Google Scholar
• Yin L, Li H, Li A-J, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61(1):82–88. doi:10.1016/j.jhep.2014.03.012
   PubMed Web of Science ®Google Scholar
• Yamakado K, Miyayama S, Hirota S, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and child-pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014;32(5):260–265. doi:10.1007/s11604-014-0298-9
   PubMed Web of Science ®Google Scholar
• Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi’s subclassification (kinki criteria). Dig Dis. 2015;33(6):751–758. doi:10.1159/000439290
   PubMed Web of Science ®Google Scholar
• Arizumi T, Ueshima K, Iwanishi M, et al. Validation of kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma. Dig Dis. 2016;34(6):671–678. doi:10.1159/000448834
   PubMed Web of Science ®Google Scholar
• Mathew EN, Nadkarni N, Choo S-P, et al. BCLC subclassification and tumour characteristics to provide prognostication of outcomes in an Asian population of locally advanced hepatocellular carcinoma treated using selective internal radiation therapy with Yttrium-90. J Clin Oncol. 2018;36(4_suppl):443. doi:10.1200/JCO.2018.36.4_suppl.443
   Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Roayaie S, Poon R, Majno PE. Dissecting EASL/AASLD recommendations with a more careful knife: a comment on “Surgical Misinterpretation” of the BCLC staging system. Ann Surg. 2015;262(1):e17–8. doi:10.1097/SLA.0000000000000398
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Zakaria HM, Macshut M, Gaballa NK, et al. Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study. Ann Med Surg. 2020;54:47–53. doi:10.1016/j.amsu.2020.04.001
   PubMed Web of Science ®Google Scholar
• Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. Oncologist. 2019;24(4):513–520. doi:10.1634/theoncologist.2018-0305
   PubMed Web of Science ®Google Scholar
• Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122(22):3430–3446. doi:10.1002/cncr.30237
   PubMed Web of Science ®Google Scholar
• Hiotis SP, Rahbari NN, Villanueva GA, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64. doi:10.1186/1471-230X-12-64
   PubMed Web of Science ®Google Scholar
• Chow PK, Choo SP, Ng DC, et al. National cancer centre Singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer. 2016;5(2):97–106. doi:10.1159/000367759
   PubMed Web of Science ®Google Scholar
• Chew XH, Sultana R, Mathew EN, et al. Real-World data on clinical outcomes of patients with liver cancer: a prospective validation of the national cancer centre Singapore consensus guidelines for the management of hepatocellular carcinoma. Liver Cancer. 2021;10(3):224–239. doi:10.1159/000514400
   PubMed Web of Science ®Google Scholar
• Zhang N, Gu J, Yin L, et al. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget. 2016;7(49):81389–81401. doi:10.18632/oncotarget.13232
   PubMedGoogle Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi:10.1038/s41598-017-12834-1
   PubMed Web of Science ®Google Scholar